ASH 2023 | Inflammatory biomarkers as predictors of CAR-T efficacy in multiple myeloma
Darren Pan
• 10 Dec 2023
Darren Pan, MD, Icahn School of Medicine at Mount Sinai, New York, NY, explores the use of inflammatory biomarkers to predict which patients with multiple myeloma (MM) will respond well to CAR-T therapy. A retrospective review revealed that patients with a high absolute lymphocyte count at baseline were more likely to develop toxicities following CAR-T treatment, and high ferritin and fibrinogen levels were associated with worse outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
